**Supplementary Material**

**Supplementary Figure 1**: Figure showing timeline of four study groups.

**Treatment as usual (TAU) Group**

**(n=28)**

**Integrated Care Pathway (ICP) Group**

 **(n=28)**

**July 2016**

**July 2010**

**Control Group 2**

**(n=36)**

 **Control group 1**

**(n=17)**

**July 2013**

**Introduction of**

**the ICP**

**Supplementary Figure 2**: Proportion of patients receiving psychotropic polypharmacy on admission and at discharge in Treatment as Usual (TAU) group, Integrated Care Pathway (ICP) group, and two control groups.

\*

N = 13/28

Legend: Polypharmacy is defined as more than one psychotropic medication. For TAU and ICP groups “psychotropics” refer to psychotropic drugs used to treat agitation/aggression only. For control groups, “psychotropics” refer to all psychotropic drugs only. \* indicates statistically significant group differences (p < 0.05) after controlling for age, gender, and number of psychotropic medications on admission in regression model. TAU; Treatment as usual, ICP- Integrated care pathway.